1. Home
  2. CMPX vs EARN Comparison

CMPX vs EARN Comparison

Compare CMPX & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPX
  • EARN
  • Stock Information
  • Founded
  • CMPX 2014
  • EARN 2012
  • Country
  • CMPX United States
  • EARN United States
  • Employees
  • CMPX N/A
  • EARN N/A
  • Industry
  • CMPX Biotechnology: Pharmaceutical Preparations
  • EARN Real Estate Investment Trusts
  • Sector
  • CMPX Health Care
  • EARN Real Estate
  • Exchange
  • CMPX Nasdaq
  • EARN Nasdaq
  • Market Cap
  • CMPX 214.6M
  • EARN 187.6M
  • IPO Year
  • CMPX N/A
  • EARN 2013
  • Fundamental
  • Price
  • CMPX $2.00
  • EARN $6.48
  • Analyst Decision
  • CMPX Strong Buy
  • EARN Hold
  • Analyst Count
  • CMPX 4
  • EARN 1
  • Target Price
  • CMPX $13.75
  • EARN N/A
  • AVG Volume (30 Days)
  • CMPX 1.8M
  • EARN 524.2K
  • Earning Date
  • CMPX 11-12-2024
  • EARN 03-05-2025
  • Dividend Yield
  • CMPX N/A
  • EARN 14.79%
  • EPS Growth
  • CMPX N/A
  • EARN 277.67
  • EPS
  • CMPX N/A
  • EARN 1.02
  • Revenue
  • CMPX $850,000.00
  • EARN N/A
  • Revenue This Year
  • CMPX N/A
  • EARN N/A
  • Revenue Next Year
  • CMPX $613.39
  • EARN $89.08
  • P/E Ratio
  • CMPX N/A
  • EARN $6.33
  • Revenue Growth
  • CMPX N/A
  • EARN N/A
  • 52 Week Low
  • CMPX $0.77
  • EARN $5.54
  • 52 Week High
  • CMPX $2.68
  • EARN $7.26
  • Technical
  • Relative Strength Index (RSI)
  • CMPX 65.48
  • EARN 42.60
  • Support Level
  • CMPX $1.43
  • EARN $6.30
  • Resistance Level
  • CMPX $2.68
  • EARN $6.68
  • Average True Range (ATR)
  • CMPX 0.24
  • EARN 0.13
  • MACD
  • CMPX 0.06
  • EARN -0.02
  • Stochastic Oscillator
  • CMPX 46.87
  • EARN 32.14

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: